Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime
The FDA just approved Eli Lilly's Foundayo (orforglipron), the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
Summarize this article with
Foundayo (orforglipron), the first GLP-1 weight loss pill with no food, water, or timing restrictions, was FDA-approved on April 1, 2026, with a list price of $649/month. Clinical trials show 7.9-12.4% body weight loss depending on dose, and it's available through LillyDirect starting April 6, 2026. Made by Eli Lilly, Foundayo is a once-daily non-peptide small molecule, fundamentally different from every other GLP-1 on the market, approved under the FDA's National Priority Voucher program in just 50 days.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality. The cheapest we track right now is $69/mo.
Compare all 54 GLP-1 providers →What Is Foundayo and Why Is It Different?
Foundayo (orforglipron) is a small-molecule, non-peptide GLP-1. Read our complete Foundayo guide for pricing, side effects, and where to buy, or compare it against the Wegovy pill receptor agonist. That technical description matters because every other GLP-1 on the market, Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, is a peptide. Peptides are large, fragile molecules that your stomach acid destroys, which is why most GLP-1s require injection.
Oral Wegovy (approved December 2025) solved part of this problem by packaging the semaglutide peptide with an absorption enhancer (SNAC), but it still requires fasting, you must take it on an empty stomach with limited water and wait 30 minutes before eating. Foundayo has none of these restrictions because it's not a peptide at all. It's a completely different type of molecule that naturally survives digestion.
| Feature | Foundayo (orforglipron) | Oral Wegovy (semaglutide) | Injectable Wegovy | Injectable Zepbound |
|---|---|---|---|---|
| Type | Small molecule pill | Peptide pill | Peptide injection | Peptide injection |
| Dosing | Once daily, anytime | Once daily, fasting required | Once weekly injection | Once weekly injection |
| Food restrictions | None | 30-min fast required | N/A | N/A |
| Refrigeration | Not needed | Not needed | May be needed | May be needed |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk | Eli Lilly |
| FDA approved | April 1, 2026 | December 2025 | June 2021 | November 2023 |
Join the list for the GLP-1 Letter.
We re-verify every price on this site against the provider's own live page and check every program against the FDA warning letter database. Join the list and you will hear from us when that work turns up something worth an email. No promised schedule until we are actually keeping one. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
How Much Weight Can You Lose? Clinical Trial Results
Foundayo's clinical trials show meaningful weight loss, though less than the injectable GLP-1s. The key Phase 3 results from the ATTAIN-1 trial:
ATTAIN-1 trial (Phase 3, 72 weeks, adults with obesity/overweight):
| Dose | Weight Loss at 72 Weeks | Achieved 10%+ Loss | Achieved 15%+ Loss |
|---|---|---|---|
| 36 mg (highest) | -12.4% | 54.6% | 36.0% |
| 12 mg | -9.3% | N/A | N/A |
| 6 mg | -7.8% | N/A | N/A |
| Placebo | -2.1% | 12.9% | 5.9% |
In the head-to-head ACHIEVE-3 trial00202-3/abstract), the orforglipron 36 mg trial capsule (described as bioequivalent to the commercial Foundayo 17.2 mg tablet) produced 9.2% weight loss vs 5.3% for oral semaglutide 14mg over 52 weeks in adults with type 2 diabetes. It also reduced HbA1c by 2.2% vs 1.4%. The 36 mg figure is a trial-formulation strength, not a patient dosing instruction.
Editor's Top Pick
Embody
from $69/mo · 7.3/10 · Compounded
Online weight-loss program that ships compounded GLP-1 medication to your door. Modern Metabolic Medicine, Inc. runs the storefront and OpenLoop Health supplies the clinical network on the current site. Embody now advertises compounded semaglutide from $79 and GLP-1 + GIP from $129; its FAQ says the chosen rate holds within a selected 4-, 12-, 24- or 52-week plan. Its standout is oral tirzepatide gum for people who do not want injections.
What Does Foundayo Cost?
| Coverage Scenario | Monthly Cost | How to Get It |
|---|---|---|
| Commercial insurance + savings card | As low as $25/mo | Foundayo savings card from Eli Lilly |
| Self-pay (lowest dose) | $149/mo | LillyDirect or retail pharmacy |
| Self-pay (higher doses) | $299/mo; $349 if the 45-day high-dose refill condition is missed | LillyDirect or retail pharmacy |
| Medicare Part D (July 2026+) | $50/mo | Medicare GLP-1 Bridge program |
| TrumpRx MFN pricing | ~$346/mo average | Included in Lilly MFN deal |
Foundayo is available in six tablet strengths: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg. Like all GLP-1s, you start at the lowest dose and gradually escalate. LillyDirect began shipping on April 6, 2026, with broader retail pharmacy availability following.
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 54 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizSide Effects
The side effect profile is similar to other GLP-1s, primarily gastrointestinal, typically improving over time:
| Side Effect | Orforglipron 36 mg trial capsule (bioequivalent to Foundayo 17.2 mg) | Placebo |
|---|---|---|
| Nausea | 33.7% | 10.4% |
| Constipation | 25.4% | 9.3% |
| Diarrhea | 23.1% | 9.6% |
| Vomiting | 24.0% | 3.5% |
Discontinuation rates due to side effects were 10.3% at the highest dose vs 2.7% for placebo. About 59% of participants reported GI symptoms overall, though most were mild to moderate and improved during dose escalation. In the ACHIEVE-3 head-to-head trial, orforglipron had higher GI event rates than oral semaglutide (59% vs 37-45%).
Who Is Foundayo For?
Foundayo is approved for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related health condition, as an addition to diet and exercise, the same criteria as Wegovy and Zepbound.
It's most compelling for patients who:
- •Refuse or fear needles, the #1 barrier to GLP-1 adoption
- •Tried oral Wegovy but struggle with the fasting/timing requirements
- •Want a simpler daily routine, take it whenever, with coffee, with meals, doesn't matter
- •Travel frequently, no refrigeration, no injection supplies needed
- •Prefer Eli Lilly's ecosystem (same company as Zepbound/Mounjaro)
If maximum weight loss is your priority and you're comfortable with injections, Zepbound (~22% loss) or the upcoming retatrutide (~29% in trials) will likely deliver more. Foundayo's value is convenience and accessibility, not raw efficacy.
How to Get Foundayo
- •LillyDirect (direct from manufacturer): Shipping started April 6, 2026. Self-pay pricing from $149/mo.
- •Telehealth providers: Several providers on our rankings are expected to add Foundayo to their offerings in the coming weeks.
- •Retail pharmacies: Broader availability rolling out throughout April-May 2026.
- •Insurance: Check with your plan. Eli Lilly's savings card can reduce copays to $25/mo with commercial coverage.
Check our provider rankings to see which telehealth platforms offer Foundayo, or use our cost calculator to estimate what you'd pay with your specific insurance.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Find your GLP-1 program, our Top Pick is Embody
Our featured pick, drawn from our independent ranking of 54 providers, is listed at from $69/mo.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 54 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
Saw Medicare mentioned in "Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime"? Here's exactly what's covered, who qualifies, and how the $50/mo Bridge copay works from July 1, 2026.
Read the Medicare Coverage Guide →Semaglutide Before and After: Weight Loss Results by Month
GuidesTirzepatide Dosage Chart for Weight Loss 2026: Complete Schedule (Zepbound, Mounjaro & Compounded)
News & PipelineCan GLP-1 Treatment Be Personalized? What New Penn and Mayo Studies Actually Show
Keep exploring
- →Provider Rankings
- →Cheapest Providers
- →Take the Match Quiz
- →Weight Loss Predictor
- →Full Cost Guide
- →Cost Calculator
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales. They are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
“More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably.”
“People with overweight or obesity have individual preferences, and with oral semaglutide as a potential new treatment option, more of those who are not on treatment today may consider starting GLP-1 treatment.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.